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Abstract
Astrocytes are critical for neuronal redox homeostasis providing them with cysteine needed for glutathione
synthesis. In this study, we demonstrate that the astrocytic redox response signature provoked by amyloid beta
(Ab) is distinct from that of a general oxidant (tertiary-butylhydroperoxide [t-BuOOH]). Acute Ab treatment
increased cystathionine b-synthase (CBS) levels and enhanced transsulfuration flux in contrast to repeated Ab
exposure, which decreased CBS and catalase protein levels. Although t-BuOOH also increased transsulfuration
flux, CBS levels were unaffected. The net effect of Ab treatment was an oxidative shift in the intracellular
glutathione/glutathione disulfide redox potential in contrast to a reductive shift in response to peroxide. In the
extracellular compartment, Ab, but not t-BuOOH, enhanced cystine uptake and cysteine accumulation, and
resulted in remodeling of the extracellular cysteine/cystine redox potential in the reductive direction. The redox
changes elicited by Ab but not peroxide were associated with enhanced DNA synthesis. CBS activity and protein
levels tended to be lower in cerebellum from patients with Alzheimer’s disease than in age-matched controls.
Our study suggests that the alterations in astrocytic redox status could compromise the neuroprotective po-
tential of astrocytes and may be a potential new target for therapeutic intervention in Alzheimer’s disease.
Antioxid. Redox Signal. 14, 2385–2397.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disor-der characterized by extracellular deposition of amyloid
beta (Ab) in senile plaques and intracellular formation of
neurofibrillary tangles leading to synaptic loss, neuronal
death, and progressive cognitive decline (32). Ab is a 40–42-
amino acid-long peptide derived from amyloid precursor
protein. The hydrophobic sequence extending from residues
25–35 in the Ab peptide are responsible for its aggregation
and its neurotoxicity (38).
Astrocytes extend between the neuronal and vascular net-
works and play critical roles in neurotransmitter, amino acid,
energy, and volume homeostasis in brain. Astrocytes also
support neuronal redox functions by providing cysteine (15),
needed for glutathione (GSH) synthesis. Although the neu-
rotoxicity of Ab is known to be mediated in part by oxidative
stress and reduced antioxidant capacity (12), the effects of Ab
on astrocytic redox metabolism are poorly characterized, de-
spite the key role played by these glial cells in neuronal redox
homeostasis under normoxic (8, 14) and stress conditions (15).
Ab activates astroglial cells, stimulating reactive oxygen
species (ROS) production, which in turn causes hyperoxida-
tion of plasma membrane proteins and lipids, impaired
glutamate clearance with consequent excitotoxicity, and dis-
ruption of the mitochondrial membrane potential (3, 12).
Cysteine limits synthesis of GSH, a major intracellular an-
tioxidant. Cysteine can be synthesized via the transsulfuration
pathway, imported into cells by a specific transporter, ASC, or
derived from cystine imported by the xc- transporter (Fig. 1a).
Cystathionine b-synthase (CBS) catalyzes the rate-limiting
step in the transsulfuration pathway (9). Faced with oxidative
stress conditions depleting the GSHpool, astrocytesmount an
autocorrective response by activating the transsulfuration
pathway and GSH biosynthesis (Fig. 1b) (47). Mature neurons
lack an efficient system for cystine uptake and rely instead on
astrocytes for provision of cysteine, which is produced from
secreted GSH (Fig. 1a) (14). GSH metabolism is critically in-
terlinked to glutamate-based neurotransmission and ion ho-
meostasis via two transporters, xC- and XAG-, and the Na
+/
K+ ATPase (Fig. 1a). Aberrations at this metabolic nexus are
associated with AD (26, 29). Using indirect methods for as-
sessing GSH, two laboratories have reported the effect of Ab
25–35 on intracellular GSH. However, their results are con-
tradictory. Abramov et al. (2) used monochlorobimane to
image GSH and reported an *50% decrease in intracellular
GSH levels after 24 h of Ab treatment. In contrast, Allaman
et al. (5), using the dithionitrobenzoic acid assay, reported an
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*300% increase in extracellular GSH with no change in in-
tracellular GSH levels after 48 h of Ab treatment. The mech-
anism of GSH extrusion and modulation of its concentration
by Ab were not investigated.
In this study, we have examined the effects of acute and
repeated Ab treatment on astrocytic GSH biosynthesis, redox
potential, and the transsulfuration pathway and compared
them with the effects elicited by tertiary-butylhydroperoxide
(t-BuOOH) treatment. We find that both short and repeated
Ab treatment induce a reductive redox potential in the ex-
tracellular milieu but an oxidative shift in the intracellular
compartment. Acute Ab treatment increased CBS levels and
enhanced transsulfuration flux in contrast to repeated Ab
exposure, which decreased CBS and catalase protein levels.
Further, Ab orchestrates an intracellular response, which is
mechanistically distinct from that of a nonspecific oxidant,
including changes in CBS and catalase protein levels and
DNA synthesis that are not seen with t-BuOOH treatment.
CBS levels and activity appear to be lower in the cerebellum
of AD brains than in age-matched controls, indicating a
pathological relevance for the ex vivo observation. These re-
sults reveal the importance of identifying disease-specific
redox signatures, which could have the potential for devel-
opment of metabolism-based disease-modifying therapeutic
approaches.
Materials and Methods
Biological samples
AD brain and age-matched control samples were from the
Michigan Alzheimer’s Disease Research Center Brain Bank. AD
samples were derived from clinically well-characterized indi-
viduals participating in a prospective brain collection program.
At death, one hemisphere was cut into 1–1.5 cm coronal slabs
and frozen rapidly over liquid N2 vapor and stored in heat-
sealed freezer bags at -80C until use. The other hemisphere
was fixed in 10% neutral buffered formalin and used for neu-
ropathologic analysis. All specimens are reviewed by the same
neuropathologist and diagnosis established by the Reagan-NIA
criteria (13). Age, gender, and postmortem delay-matched con-
trol specimens were derived from individuals with no clinical
history of neurologic disease and normal neuropathologic ex-
aminations. Slabs were warmed to -20C and blocs of frontal
cortex and cerebellum were prepared. The University of
Michigan’s Committee on Use and Care of Animals approved
the protocol used in this study for handling animals.
Isolation and preparation of murine primary cells
Primary murine cortical astrocytes cultures were prepared
from 1- to 2-day-old Balb/c pups as described previously (20,
FIG. 1. The effects of specific versus general oxidants on the astrocytic thiol-based redox metabolism. (a) Pathway for
thiol-based redox metabolism. PPG, SAS, AbH, Aza, ACV, and MK-571 are inhibitors of c-cystathionase, c-glutamylcysteinyl
synthetase, the xC- transporter, the XAG- transporter, ASC neutral amino acid transporter, c-glutamyl transpeptidase (cGT),
and the multidrug resistance protein 1 (MRP1), respectively. (b) Differences in the redox responses elicited by Ab versus
t-BuOOH. Green lines and fonts denote metabolites or activities that increase in response to acute or repeated treat-
ment conditions; blue denotes a decrease under acute and repeated Ab but not t-BuOOH treatment conditions, and red
denotes a decrease only with repeated Ab treatment. Black lines and text represent denote parameters in which no changes
were observed. (c) Scheme showing the treatment regimens for acute versus repeated exposure to Ab or t-BuOOH. Ab,
amyloid beta; AbH, aspartate-b-hydroxamate; ACV, acivicin; Aza, azaserine; PPG, propargylglycine; t-BuOOH, tertiary-
butylhydroperoxide; SAS, sulfasalazine.
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21). At the end of the third passage, cells were seeded in 6-well
(2 · 106 cells/well/2ml), 24-well (5· 105 cells/well/ml), or
48-well plates (5· 104 cells/well/0.4ml), or a 8-well chamber
slide (1 · 105 cells/well/0.4ml), depending on the experi-
ment, and incubated for a week (with half the medium being
changed every third day). The purity of astrocytes was de-
termined as described previously (21) and wasq93%.
Dissociated neurons were prepared as described previously
from embryonic day 16 (E16) to E18 mice and cultured (1· 105
cells/well/0.5ml) in neurobasal media containing B27 (1· )
supplement, 2mM L-glutamine and penicillin–streptomycin
(100 units/ml and 100lg/ml final concentration, respectively)
on laminin (Invitrogen) and poly-D-lysine (Sigma)-coated glass
cover slips (12 mm; Bellco Glass) in 24-well plates (20, 21). The
purity of neurons was assessed by staining with antibody to
anti-b III tubulin (TUJ1) and found to be > 95% as observed
microscopically.
Aggregation of Ab peptide
The lyophilized form of the triflouroacetate salt of the Ab
peptide (25–35, or 1–42 Bachem) was aggregated as described
previously (37). Briefly, Ab was dissolved in sterile double-
distilled water as a 2mM stock solution, incubated for 8 days
at 37C, and stored in aliquots at - 80C. Soluble Ab (2mM)
was prepared by dissolving lyophilized peptide in 1% di-
methyl sulfoxide and stored immediately at - 80C.
Ab treatment of primary astrocyte cultures
At the start of experiments, astrocytes were replenished
with fresh astrocyte media (Dulbecco’s modified Eagle’s me-
dium/F12 + 2mM L-glutamine + 10% heat inactivated fetal
bovine serum +penicillin-streptomycin (100 units/ml and
100 lg/ml final concentration, respectively). For the acute
treatment, a single bolus of 200lM t-BuOOH or 50lM Ab
(25–35) or 10 lM Ab (1–42) was added and incubation was
continued for the desired times (Fig. 1c). For the repeated
treatment model, astrocytes were stimulated with 50 lM Ab
(25–35) or 10 lM Ab (1–42) repeatedly (3 bolus treatments,
once every 72 h), and experimental analysis was started after
the third Ab treatment (Fig. 1c). Cell death was observed in
< 10% of astrocytes after acute or repeated Ab treatment as
monitored by the PI-AV labeling kit (data not shown; BioVi-
sion) and TUNEL assay kit (Roche) according to the vendor’s
protocol. Sulfasalazine (SAS, 500 lM), MK571 (100 lM),
acivicin (400lM), azaserine (500lM), and aspartate-b-
hydroxamate (400lM) (Sigma) when used were added in a
single bolus at the start of the acute Ab treatment or the third
exposure to repeated Ab treatment regimen. The effect of Ab
dose on astrocyte viability and metabolite levels was deter-
mined after a single bolus treatment with 1, 10, or 50lM Ab
(acute model) or with the same Ab concentrations but ad-
ministered using the repeated treatment regimen described
above. To study the response of the transsulfuration pathway
during acute and repeated stimulation with either t-BuOOH
or Ab, cells were incubated with L-(35S)-methionine (Perkin
Elmer) to a final concentration of 2lCi/ml in the presence or
absence of 2.5mM propargylglycine for 6 or 12 h. At the in-
dicated time points, culture supernatants were removed and
used immediately for H2O2 analysis or stored frozen at - 80C
until used for determination of extracellular thiols. Cells were
harvested and frozen at - 80C until further use.
CBS analysis in the human brain samples
Frozen brain tissue (*300mg) was pulverized in liquid N2
and CBS activity and protein expression in the postmortem
brain samples of patients with AD and age-related normal
subjects were analyzed as described previously (46).
Metabolite analyses
Extracellular thiols (cystine, cysteine, and GSH) in cell culture
medium were quantified in metaphosphoric acid-fixed protein-
free supernatant as described previously (20, 35). Intracellular
GSH and incorporation of (35S) from methionine into GSH was
quantified as described previously (20, 35). The results were
normalized to the protein concentration in each sample.
(3H)-thymidine incorporation assay
Astrocytes (5 · 104/well) were seeded at *50%–70% con-
fluency in 48-well plates at day 0. After stimulation with Ab
(25–35) or t-BuOOH for 2 h, cells were incubated with (3H)-
thymidine (1 lCi/ml; Perkin Elmer) for a further *24 h at
37C. Cells were washed twice with phosphate-buffered sa-
line (PBS) and dissolved in 100 ll NaOH (0.2M). The samples
were mixed with scintillation cocktail and radioactivity in-
corporation was measured.
Western blot analysis
Astrocytes with the indicated treatments and at the desired
time points were harvested and lysed on ice as described pre-
viously (19). Antibodies against CBS, catalase, superoxide dis-
mutase 1 (SOD1) (Abcam), actin (Sigma), and xCT, the catalytic
subunit of xC- (Novus Biological), were used to monitor ex-
pression of the respective protein antigens anddetectedusing the
Dura chemiluminescent horseradish peroxidase system (Pierce).
Determination of extracellular H2O2
and intracellular ROS
Astrocytes were treated with a single bolus of the 25–35Ab
peptide for 3 and 24h acutely or repeatedly as described above.
To check the effect of antioxidant on ROS production, astrocytes
were pre-treated or not with 1mMN-acetyl cysteine (NAC) for
24h and then incubated with Ab 25–35 (50lM) or 1–42 (10lM)
for 3h. Alternatively, astrocytes were transfected with catalase-
His-V5-expressing pCDNA3.1 (a generous gift from Brent Car-
ter, University of Iowa) or the empty pCDNA3.1 plasmid using
TransIT-2020 reagent (Mirus) as per the manufacturer’s proto-
col. After 24h post transfection, cells were incubated with Ab
25–35 (50lM) or 1–42 (10lM) in fresh media for 3h. After Ab
stimulation, the astrocyte conditioned medium was saved for
extracellular H2O2 determination, whereas the cells were used
for intracellular ROS detection using the Image-iT Live Green
ROS Detection Kit as per the manufacturer’s protocol (Invitro-
gen). Briefly, cells werewashed twicewith Ca2+ - andMg2+ -free
Hank’s balanced salt solution (HBSS), followed by incubation
with 5-(and-6)-carboxy-2¢,7¢-dichlorodihydrofluorescein diace-
tate (Invitrogen) at a final concentration of 5lM for 30min at
37C. Cells were washed once with HBSS and incubated with
Hoechst 33342 nuclei stain (1:200 dilution, excitation 365nm,
emission 480nm; Invitrogen) for 10min at 37C to ensure
equal cell numbers. Cells were washed three times with HBSS
followed by lysing using the lysis buffer. An aliquot of lysate
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(100ll each) was transferred to a fluorimetric plate, the fluores-
cence excitation/emission maxima were recorded at 495/529nm
and the results expressed as F529/F480nm. The concentration of
H2O2 in the conditioned media was measured using the Amplex
Red reagent kit as per the manufacturer’s protocol (Molecular
Probe). Conditioned media (100ll) in a 96-well fluorimetric plate
was mixed with 10lM Amplex red reagent and 1U/ml horse-
radish peroxidase at a 1:1 ratio and incubated for 30min at room
temperature. A standard curve was generated with known con-
centrations (50nM to 10lM) of H2O2. The amount of resorufin
produced by Amplex Red oxidation was determined fluorime-
trically (excitation: 544nm, emission: 590nm). Background fluo-
rescence was determined for the medium control and subtracted
from each value and results were expressed as the concentration
of H2O2 in the medium.
Analysis of apoptosis
The terminal deoxynucleotidyl transferase-dUTP nick end
labeling (TUNEL) assay (Roche Diagnostics) was employed as
previously described (20). Briefly, astrocytes were cultured in
24-well plates and treated acutely or repeatedly with 50lM
(25–35) or 10lM (1–42) Ab as described above. After incuba-
tion, 500ll of each conditioned media was transferred on to
neuronal monolayers in 250ll neuronal media in the presence
or absence of 50lM Ab (25–35). Neurons were incubated for
another 12–14h followed by labelingwith the TUNEL stain. To
check the effect of Ab or t-BuOOH on viability, astrocytes were
treated with different concentrations of Ab (25–35) peptide (1,
10, 50lM) or t-BuOOH (200, 400, 800lM) for 12–14h followed
by labeling with the TUNEL stain. Nuclei were observed with
Hoechst stain (1:200 dilution, excitation 365nm, emission
480nm; Invitrogen) and quantitative analysis was performed
by counting > 2000 cells as described previously (20).
Analysis of mitochondrial activity
To check the effect of Ab on astrocytic mitochondrial activity,
the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay was employed as previously described (47).
In brief, astrocytes (1·106/well) in 24-well plates were treated
with different concentration of Ab (25–35) acutely or repeatedly.
After stimulation for *20h, cells were washed with PBS and
incubated with MTT dye (0.5mg/ml) for 2h at 37C, followed
by washing with PBS. Cells were dissolved in dimethyl sulfox-
ide. Optical density was measured at 553nm and the back-
ground was corrected after reading the absorbance at 650nm.
Statistical analyses
The significance of the differences in data between control
and experimental groups was determined by one-way anal-
ysis of variance followed by post-test Bonferroni adjustment.
Students t-test (paired, two-tailed) was also performed for
comparison with the analysis of variance test. p< 0.05 was
considered to be statistically significant.
Results
Protracted increase in astrocytic ROS production by Ab
Since the kinetics of Ab-induced ROS production by as-
trocytes and microglia have previously been monitored only
on a short time scale (3, 24), we examined the intracellular
ROS and extracellular H2O2 levels on a longer time scale
during which metabolic changes are typically observed
(Fig. 2). Acute Ab treatment was reported to induce an *2-
fold increase in ROS levels 30min after exposure (3). We
found similarly increased ROS levels even at 3 h after acute Ab
(25–35) exposure, but the levels declined to control values
after 24 h (Fig. 2a). In contrast, intracellular ROS levels were
*3- and *5-fold higher at the same times after the last Ab
(25–35) addition in the repeated treatment regimen (Fig. 2a).
Since ROS are typically short-lived, these results reveal that
both acute and repeated Ab-treatment regimens provoke
sustained ROS production spanning several hours. ROS
production is paralleled by increased extracellular H2O2, with
the kinetics of H2O2 increase and dissipation varying with the
treatment regimen. Extracellular H2O2 levels were *4-fold
higher after 24 h of acute and *2-fold higher after 24 h of
repeated Ab treatment (Fig. 2b). The longer Ab (1–42) peptide
increased intracellular ROS by*50% and extracellular H2O2
by *65% after 3 h of treatment (Fig. 2c, d). Addition of the
antioxidant, NAC, a cysteine precursor, or over expression of
catalase, a peroxide scavenger, decreased Ab-mediated over
production of ROS (Fig. 2c, e) and H2O2 (Fig. 2d, f). When
freshly prepared 50lM Ab (25–35) was used instead of the
aggregated form, it failed to induce over production of in-
tracellular ROS and extracellular H2O2 (Fig. 2g, h). Catalase,
SOD, and GSH peroxidase are major antioxidant enzymes in
mammalian cells that clear ROS. We checked the expression
levels of two of these antioxidant enzymes and found that
repeated but not acute Ab (25–35) treatment decreased stea-
dy-state levels of catalase, whereas Cu/Zn SOD1 was un-
changed by either treatment (Fig. 2i). In contrast, neither acute
nor chronic t-BuOOH treatment affected catalase or SOD1
expression levels (Fig. 2i). Since the magnitude of ROS stim-
ulation seenwithAb (25–35) and (1–42)was similar, andNAC
similarly abrogated ROS accumulation, further experiments
were conducted with the shorter peptide.
Differential responses in transsulfuration and GSH
synthesis pathways to acute versus repeated
Ab treatment
One mechanism by which human astrocytes respond to
oxidative stress induced by t-BuOOH is by increasing flux
through the transsulfuration pathway (47), which furnishes
cysteine and results in increased GSH synthesis. In murine
astrocytes, acute t-BuOOH or acute Ab (25–35) stimulation
also induced GSH synthesis at levels that were comparable at
6 and 12 h (Fig. 3a). When freshly prepared 50 lM soluble Ab
(25–35) was used, no change in GSH levels was observed at
6 h (Fig. 3b). An *50% increase in radiolabel incorporation
from (35S)-methionine to GSHwas observed in 6 h upon acute
t-BuOOH or acute Ab stimulation (Fig. 3c) that was inhibited
*2-fold by propargylglycine, a suicide inhibitor of c-
cystathionase, the second enzyme in the transsulfuration
pathway (Fig. 1a), demonstrating the role of this pathway in
the astrocytic response to acute oxidative challenge. In con-
trast, GSH levels were unchanged by repeated treatment
with either t-BuOOH or Ab (25–35) after 6 h and diminished
*20% with Ab after 12 h (Fig. 3a). Repeated Ab treatment
(25–35) resulted in an *2-fold decrease in the transsulfura-
tion flux (Fig. 3d). Glutathione disulfide (GSSG) levels were
*3-fold higher in response to t-BuOOH at 6 h but normal-
ized to control levels at 12 h (Fig. 3e). In contrast, acute Ab
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treatment (25–35) caused a slower increase in GSSG levels,
which were 20% higher at 6 h and twofold higher at 12 h in
comparison to the untreated control. An effect on the GSSG
concentrationwas not observedwith repeated t-BuOOH and
Ab treatment. As a result of the varied responses in the GSH
and GSSG pool with different treatments, the GSH:GSSG
ratio, an indicator of the intracellular redox poise, initially
decreased in response to acute (*30%) and repeated (*50%)
t-BuOOH treatment at 6 h but subsequently overshot control
values at 12 h (Fig. 3f). In contrast, both acute and repeated
Ab treatments resulted in an oxidative shift in the intracel-
lular GSH/GSSG ratio.
CBS catalyzes the committing step in the transsulfuration
pathway andWestern blot analysis revealed that CBS protein
levels increase in response to acute treatment with Ab (25–35)
but decrease in response to repeated treatment (Fig. 3g). In
contrast, neither acute nor repeated t-BuOOH affected CBS
levels. Hence, the astrocytic redox responses to Ab versus an
organic peroxide challenge and to acute- versus repeated ex-
posure to Ab are distinct.
Ab induces oxidative remodeling of the intracellular
GSH/GSSG redox potential
The GSH/GSSG potential is initially slightly oxidized at 6 h
in response to acute ( - 241mV) and repeated (- 244mV) t-
BuOOH treatment compared with control (- 247mV) but
subsequently overshoots the control value by appoximately
- 10mV at 12 h (Fig. 3h). In contrast, acute Ab treatment
(25–35) results in an oxidative shift in the GSH/GSSG po-
tential to - 237mV at 12 h, whereas repeated Ab treatment
elicits the same change within 6 h.
Ab induces reductive remodeling of the extracellular
cysteine/cystine redox potential
The cysteine:cystine ratio is a key determinant of the ex-
tracellular redox poise (33). Hence, the kinetics of extracellular
cystine consumption and cysteine accumulation were moni-
tored and were strikingly more rapid in the presence of Ab
(25–35) than in untreated controls (Fig. 4a, b) and dependent
on the dose of Ab (Fig. 5a, b). Ab (1–42) caused similar
changes in cysteine and cystine (data not shown). Levels of
xCT, the catalytic subunit of the primary cystine transporter,
xC-, were not affected by acute Ab (25–35) treatment but were
downregulated > 4-fold with repeated Ab treatment (Fig. 4c).
Neither acute nor repeated t-BuOOH treatment influenced
xCT levels (Fig. 4c) or affected cystine consumption signifi-
cantly (data not shown). The cysteine/cystine redox couple is
important for controlling the redox poise in the extracellular
space. The extracellular cysteine/cystine redox potential
in untreated cells was estimated to be appoximately - 80mV
at 2 h. After 6 h of culture, the redox potential decreased to
- 90mV (untreated controls) versus - 105mV (acute Ab
treatment) and - 124mV (repeated Ab treatment), indicating
a more reducing environment (Fig. 4d) and the magnitude of
the reductive shift was dependent on the dose of Ab (Fig. 5c).
As expected, t-BuOOH caused cysteine oxidation and the
redox potential increased to a more positive value at 2 h but
normalized to control values in 6 h (Fig. 4d). Neither acute nor
repeated t-BuOOH treatment altered the extracellular GSH
concentration, whereas a time-dependent increase in extra-
cellular GSH was observed in response to Ab treatment (Fig.
4e), which was dependent on the dose of Ab (Fig. 5d). Thus,
FIG. 2. Antioxidant (NAC or catalase) treatment abrogates Ab-mediated ROS generation in astrocytes. (a, b) Astrocytes
(AG) were incubated with none (white bar), 50 lM Ab 25–35 acute (gray bar), or repeated (black bar), and intracellular ROS
levels (a) and extracellular H2O2 (b) were measured either 3 or 24 h later. Astrocytes were either treated with 1mM NAC or
transfected with a catalase expression or empty vector for 24 h and then treated with either 10lM Ab 1–42 (c, d) or 50 lM Ab
25–35 (e, f) for 3 h and intracellular ROS (c, e) and extracellular H2O2 (d, f)were measured. (g, h) Freshly prepared soluble Ab
(gray bar, S-Ab, 25–35) does not provoke ROS (g) and H2O2 (h) production in astrocytes, respectively. (i) The effect of Ab (25–
35) versus t-BuOOH treatment on astrocytic catalase and SOD1 expression. Data are the mean– SD representative of two
independent experiments each performed in triplicate. *pp0.05, **pp0.01, ***pp0.001; ns, not significant. NAC, N-acetyl
cysteine; ROS, reactive oxygen species; SOD, superoxide dismutase.
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the metabolic response both inside and outside the cell to Ab-
induced increase in ROS levels results in reductive remodel-
ing in the extracellular compartment.
Ab induces DNA synthesis
Since a reductive shift in the extracellular potential is usually
correlated with cell proliferation, the effect of Ab (25–35) on
DNA synthesis was assessed. Like dendritic cells that remodel
the extracellular redox potential to support T cell proliferation
(49), the astrocytic response to Ab might similarly stimulate a
proliferative glial response. Acute Ab treatment increased (3H)-
thymidine incorporation into DNA by *50% (Fig. 6) as seen
previously (27), while a robust 300% increase was observed
with repeated Ab treatment. In contrast, t-BuOOH decreased
(3H)-thymidine incorporation into DNA modestly when ap-
plied as a single bolus, whereas repeated t-BuOOH treatment
resulted in a 200% decrease (Fig. 6).
Intracellular GSH is source of extracellular cysteine
Extracellular cysteine is derived from the breakdown of
secreted GSH via the c-glutamyl pathway (49). To establish
the involvement of this pathway in the astrocytic response to
Ab (25–35), we employed pharmacological inhibition at
various steps (Fig. 1a). Inhibition of cystine import with
SAS, GSH export with MK-571, or extracellular GSH
cleavage with acivicin significantly decreased extracellular
cysteine accumulation (Fig. 7a). In contrast, inhibition of
XAG-, which has a low affinity for cysteine, or inhibition of
ASC, the neutral amino acid transporter, did not have a
significant effect on extracellular cysteine accumulation. Of
these inhibitors, only SAS and to a smaller extent, MK-571,
diminished cystine consumption from the medium (Fig. 7b).
whereas the decrease in cystine consumption in the pres-
ence of SAS is expected, the effect of MK-571 might be in-
direct, that is, by inhibiting GSH efflux, it inhibits cystine
uptake.
Ab does not cause astrocytic apoptosis but decreases
mitochondrial activity
Ab-mediated cellular toxicity and apoptosis are reported in
AD (3, 5, 6) and primary neurons are very sensitive to Ab-
induced apoptosis. Astrocytes exposed to 50lM Ab (25–25)
FIG. 3. Astrocytes upregulate the transsulfuration pathway during acute treatment with t-BuOOH or Ab. Astrocytes
(AG) were treated with either none (white bar) or acutely with a single bolus of either 200 lM t-BuOOH (gray bar) or 50 lMAb
(25–35, black bar) and incubated together with (35S)-methionine – 2.5mM PPG for 6 and 12 h. To compare the GSH level under
acute and repeated treatment, astrocytes were either untreated or treated acutely or repeatedly with 200lM t-BuOOH or
50 lM Ab (25–35). At the indicated times, cells were harvested and intracellular (GSH) (a), (GSSG) (e) and radioactivity
incorporation in GSH (c, d), were measured, normalized to protein level and ratio of GSH/GSSG was calculated (f).
Intracellular (GSH) in untreated astrocytes was 298 – 87 pmol/lg protein and 354 – 141 lmol/g protein at 6 and 12 h, re-
spectively. The radioactive counts in GSH were 691 – 94 cpm/lg protein and 1096– 284 cpm/lg protein at 6 h and 12 h post-
incubation with (35S)-methionine. (b) shows the effect of freshly dissolved soluble 50 lM Ab (black bar, S-Ab, 25–35) on
astrocytic GSH. The Western blot data in (g) shows CBS in astrocytes after acute or repeated treatment with either t-BuOOH
or Ab (25–35) for 24 h. (h) shows the intracellular GSH/GSSG redox potential that was calculated using the Nernst equation:
Eh=Eo +RT/nF ln ([GSSG]/[GSH]2), using Eo = - 240mV (pH = 7.4). Data are represented as % mean – SD of 5 (a, c, d, h) or 2
(b, g) or three independent experiments (e, f), each performed at least in duplicate on different batches of cells. *,pp0.05;
**,pp0.01; pp0.001; ns, not significant. Asterisks (*) denote the level of significance in the comparison between untreated
versus treated conditions, whereas the open circles () represent the comparison between acute and repeated treatments with
the same agent. GSH, glutathione; CBS, cystathionine b-synthase; GSSG, glutathione disulfide.
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are resistant to apoptosis after exposure to Ab (25–35) as
monitored by the TUNEL (Fig. 8a) or Annexin-V (data not
shown) assays. In contrast, 800lM t-BuOOH induced apo-
ptosis in *80% of the astrocytes but not at 400lM (not
shown) as measured using the TUNEL assay. Interestingly,
the MTT assay, a reporter of mitochondrial activity, showed a
dose-dependent decrease (*10%–35%) in response to Ab (25–
35) treatment, which was concentration dependent (Fig. 8b).
In contrast, 200lM t-BuOOH did not show a significant re-
duction of MTT (data not shown).
FIG. 4. Changes in the extracellular cysteine/cystine redox potential in response to t-BuOOH or Ab treatment. Astrocytes
were either untreated (circle or while bar) or treated acutely (square or gray bar) or repeatedly (triangle or balck bar) with 50 lM
Ab (25–35) or 200lM t-BuOOH. Extracellular cysteine (a), cystine (b), and GSH (e) concentrations were determined in
aliquots removed from the culture medium. In (a), the concentration of cysteine in the medium at time 0 (15– 5.7 lM) was
subtracted from the values at all time points. (c) shows the effect of Ab versus t-BuOOH treatment on astrocytic xCT
expression. (d) The extracellular cysteine/cystine redox potential when astrocytes were treated with 200 lM t-BuOOH or
50 lM Ab was calculated using the Nernst equation (Fig. 3 legend), using Eo = - 250mV (pH = 7.4). Data are the mean – SD of
4 (a, b, d, e) or 2 (c) independent experiments performed on different batches of cells. Asterisks (*pp0.05, **pp0.01,
***pp0.001) denote the level of significance in the comparison between untreated and treated conditions. ns, not significant.
FIG. 5. Dose dependence of Ab on
the extracellular cysteine/cystine re-
dox couple. Astrocytes were either
untreated (white bar), or treated acutely
(gray bar) or repeatedly (black bar) with
1, 10, and 50lM of Ab (25–35). At the
indicated time, an aliquot of culture
supernatant was collected and extra-
cellular cysteine (Cys) (a), cystine
(Cys2) (b), and GSH (d) were mea-
sured, and the redox potential (c) was
calculated as described in Fig. 4 leg-
end. Data are mean – SD from two
independent experiments each per-
formed in triplicate on different bat-
ches of cells. Asterisks (*pp0.05,
**pp0.01, ***pp0.001) denote level of
significance and are shown only if
there was a statistically significant
difference and represent the compari-
son between untreated controls and
treated conditions.
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Repeated Ab treatment abrogates the neuroprotective
effect of astrocytes
Cysteine enhances GSH synthesis in neurons and is a
known neuroprotectant (15). Since Ab stimulates extracellular
cysteine accumulation by astrocytes, the effect of astrocyte-
conditioned media on protecting neurons from Ab-induced
apoptosis was examined. For this, astrocytes were stimulated
acutely or repeatedly with 50lMAb (25–35) or 10 lMAb (25–
35) as described under theMaterials andMethods section and
after 12–14 h of incubation, conditioned medium was re-
moved and transferred onto neuronal monolayers in the
presence or absence of 50lM Ab for 12–14 h after which ap-
optosis was assessed by the TUNEL assay (Fig. 9). Unlike
astrocytes that were not found to undergo apoptosis in re-
sponse to 50lM Ab treatment (Fig. 8a), *50% neuronal cell
death was observed. Conditioned medium from untreated or
acutely treated astrocyte cultures afforded similarly modest
but significant protection of neurons from apoptosis com-
pared with fresh medium (Fig. 9a, b). In contrast, when con-
ditioned medium from astrocyte cultures exposed to repeated
Ab treatment was used, the neuroprotective effect was abro-
gated (Fig. 9a, b). The effect of astrocyte-conditioned medium
from cultures that had received either acute or repeated Ab
treatment regimens on survival of neurons that had not been
exposed to Ab was assessed (Fig. 9c). Conditioned media
from either untreated or acutely treated astrocytes (with either
Ab 25–35 or 1–42) did not cause neuronal toxicity. However,
conditioned media from astrocytes exposed to the repeated
Ab regimen caused significant neuronal apoptosis (Fig. 9c).
Notably, the extent of chronic Ab 1–42-mediated apoptosis
was considerably lower than for Ab 25–35 (Fig. 9c).
Changes in CBS levels and activity in AD brain
Immunohistochemical localization of CBS in adult murine
brain reveals weak and diffuse labeling with the exception of
the hippocampus and cerebellum, where the labeling is in-
tense (42). Since cerebellar and cortical tissues from AD pa-
tients and age-matched controls were more readily available
than hippocampal tissue, we compared CBS activity and
protein levels in these samples (Fig. 10). Although differences
were not observed in the frontal cortex, cerebellum from AD
patients tended to exhibit both lower CBS expression (Fig.
10a, b) and activity (Fig. 10c). However, due to high variations
and relatively low sample number, the difference did not
reach statistical significance. Moreover, differences in CBS
protein level and activity between AD and healthy subjects
did not correlate with sex, age, and postmortem time of the
individual specimens (Supplementary Table S1; Supplemen-
tary Data are available online at www.liebertonline.com/ars).
Discussion
While oxidative stress is a nonspecific hallmark of many
neurodegenerative diseases (6), the sequelae of specific redox
potential changes in the intra- versus extra-cellular compart-
ments that govern disease-specific signaling and metabolic
responses are unknown. Since H2O2 is reported to mediate Ab
FIG. 6. DNA synthesis is induced by Ab but not by per-
oxide. After acute or repeated treatment with Ab or t-
BuOOH, cells were incubated with (3H)-thymidine (1 lCi) for
*24 h at 37C, before radioactivity incorporation was mea-
sured. Data are mean – SD from two independent experi-
ments each performed in triplicate on different batches of
cells. Asterisks (*) represent the level of significance for
comparison between untreated and treated samples as in-
dicated in Fig. 5 legend.
FIG. 7. The c-glutamyl cycle is a
primarily responsible for cysteine
release from astrocytes. Astrocytes
(AG) were either untreated (white bar),
or treated acutely (gray bar) or repeat-
edly (black bar) with 50lM Ab (25–
35)–different inhibitors. At 24 h post-
incubation, an aliquot of the culture
supernatant was collected and extra-
cellular (Cys) (a) and (Cys2) (b) were
measured. Data are the mean– SD
from 3 independent experiments each
performed in duplicate on different
batches of cells. Asterisks (*pp0.05,
**pp0.01, ***pp0.001) denote statistical significance in extracellular (Cys) between AG control – inhibitors or AG+Ab
acute – inhibitors or AG+Ab repeated – inhibitors. ns, not significant.
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toxicity (11), we investigated thiol-based redox responses of
astrocytes to Ab versus the organic peroxide, t-BuOOH,
and discovered that they elicit significantly different effects
(Fig. 1b).
Cellular functions such as proliferation, differentiation, and
death signals are modulated in part by the intracellular and
extracellular redox potentials (43). Mammalian cells have
multiple redox buffering systems (22). The redox potential of
the extracellular compartment is regulated dynamically
by intracellular redox metabolism, and, in contrast to the
importance of the GSH/GSSG redox couple inside the cell,
the cysteine/cystine redox pair is quantitatively the most
FIG. 8. Ab does not cause astrocytic cell death but impairs the mitochondrial activity in a dose-dependent manner. (a)
After stimulation with Ab (50lM; 25–35) or t-BuOOH (800 lM), the extent of astrocytic apoptosis was determined using the
TUNEL assay. To permit quantitative analysis, nuclei were stained with Hoechst stain (excitation 365 nm, emission 480 nm).
Red and green colors show staining for nuclei and apoptotic cells respectively. Merge represents the overlap of red and green;
BF denotes bright-field contrast enhancement of the merged image. (b) After addition of different concentrations of Ab (25–
35, acute or repeated) stimulation for*20 h, cells were washed with phosphate-buffered saline, and incubated with MTT dye
(0.5mg/ml) for 2 h at 37C, followed by washing in phosphate-buffered saline, dissolving in dimethyl sulfoxide, and reading
the optical density at 553 nm. (a) shows representative data from two independent experiments. (b) shows data as mean– SD
from 3 independent experiments each performed in triplicate on different batches of cells. *pp0.05, **pp0.01, ns =not
significant. TUNEL, terminal deoxynucleotidyl transferase-dUTP nick end labeling.
FIG. 9. Repeated Ab treatment abrogates the neuroprotective effect of astrocytes. Primary murine cortical neurons were
treated (a, b) or untreated (c) with Ab (50lM) for *14 h in the presence of either fresh or conditioned medium from
astrocytes that were either untreated or treated with either 25–35 (a, b) or 1–42 (c) Ab (acute or repeated) for 12–14 h. Bar
graphs represent the mean – SD of apoptotic neuronal cells measured by TUNEL labeling as a percentage of total cells
(labeled by Hoechst). (a) Representative micrographs of apoptotic neurons are presented. (b,c) Quantitative analysis of
microscopic data from 2 independent experiments. For statistical analysis, at least 1000–2000 cells were counted from each
experiment and are shown as mean– SD. *pp0.05, **pp0.01, ***pp0.001, ns, not significant.
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significant thiol-based redox buffer outside the cell (33). A
reductive shift (i.e., to a more negative redox potential value)
is associated with cellular proliferation, whereas an oxidative
shift correlates with cell death (33). Our results, that is, that Ab
treatment induces a reductive shift, in contrast to a general
oxidant, in the extracellular redox potential in astrocytic cul-
tures, suggest that a similar response in the CNS might
stimulate proliferation of microglia, exacerbating neuronal
degeneration. In fact, inflammation is considered to contrib-
ute to neuronal demise in AD (4).
Our study also reveals that the astrocytic redox response to
Ab stimulation is complex anddistinct in the intra- versus extra-
cellular compartments. Paradoxically, elevated H2O2 levels are
observed under conditions where there is a net shift in the
extracellular redox potential in the reductive direction in re-
sponse to Ab treatment (Figs. 3–5), emphasizing the impor-
tance of analyzing metabolic responses to oxidative stress in
the context of the redox milieu in addition to the levels of the
individual oxidant species. Ectodomains ofmembrane proteins
are rich in disulfide bonds, and the*30mV decrease in redox
potential induced by repeated Ab treatment (Figs. 4 and 5) is
expected to result in a 10-fold shift in the equilibrium from the
disulfide to the dithiol state. The redox state of receptors and
transporters influence both their structure and function and
the Ab-induced reductive shift is likely to have pleiotropic
consequences on signaling pathways emanating from redox-
sensitive membrane protein targets that await elucidation.
An interesting parallel in extracellular reductive remodeling
is seen with dendritic cells during activation of T cells and
results from increased cystine consumption and extracellular
cysteine secretion without enhanced transsulfuration flux (49).
The released cysteine is used by naı¨ve T cells, which, like
neurons, are unable to efficiently transport cystine. In the CNS,
cysteine accumulation, if unchecked, might lead to N-methyl
D-aspartate receptor excitoxicity (36). We speculate that the
threshold between a neuroprotective versus toxic concentration
of cysteine may be crossed if astrocytes are overactivated by
repeated Ab stimulation. As previously shown with dendritic
cells, the c-glutamyl cycle is also the source of extracellularGSH
and cysteine in astrocytes (49). Inhibition of the xC- antiporter,
the GSH exporter or c-glutamyltranspeptidase all lead to lower
extracellular cysteine accumulation (Fig. 7a).While secretion of
extracellular thioredoxin by dendritic cells during T cell acti-
vationwas proposed to contribute to cysteine accumulation (7),
subsequent studies have ruled out a role for thioredoxin in this
process (49). Additional redox systems not examined in this
study are also likely to contribute to the redox remodeling in-
duced byAb, For instance, a Cu-Zn-type extracellular SOD has
been shown to delay oxidation of extracellular GSH (45).
The profiles of intracellular redox responses elicited by
acute versus repeated exposure to Ab are also distinct from the
corresponding response triggered by t-BuOOH (Fig. 1b). As-
trocytes responded to peroxide treatment by a compensatory
increase in GSH synthesis, without affecting CBS enzyme le-
vel, leading to a net reductive shift in the intracellular GSH/
GSSG potential (Fig. 3). Although t-BuOOH treatment does
not affect CBS levels, flux through the transsulfuration flux is
increased and could result from changes either up- or down-
stream of CBS, which remain to be elucidated. The GSH:GSSG
ratio is initially diminished in response to acute (*30%) and
chronic (*50%) t-BuOOH treatment at 6 h but subsequently
overshoots the control values at 12 h (Fig. 3h). In an auto-
corrective response, cells increase GSH synthesis to counter
oxidative stress, leading to more reducing redox potential at
12 h. Cells treated repeatedly with t-BuOOH show a different
response, that is, lower GSSG levels (Fig. 3e). The net result,
nevertheless, is more reducing conditions.
In contrast, both acute and repeated Ab treatment resulted
in an oxidative shift in the GSH/GSSG redox potential. With
acute Ab treatment, the decline in the redox potential was
driven by the time-dependent increase in GSSG levels,
whereas with repeated Ab treatment, the concentration of
GSSG increased transiently before returning to control levels
(Fig. 3e). However, the concentration of reduced GSH also
FIG. 10. CBS activity and protein expression levels are
diminished in cerebellum of AD patients. (a) Representative
Western blot analysis showing CBS levels in postmortem
cerebellum of AD patients and age-matched normal indi-
viduals. N and AD denote normal and AD samples, respec-
tively. (b) The average CBS protein levels (n= 8), and (c) the
average CBS activity in postmortem samples of frontal cortex
(n= 10) and cerebellum (n= 12 and 16 for normal and AD
samples respectively), obtained from AD patients and age-
matched normal individuals. The CBS protein levels were
quantified from Western blots. AD, Alzheimer’s disease.
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decreased over time with chronic Ab treatment, which re-
sulted in a lower redox potential. The difference between the
acute versus repeated response to Ab suggests that metabolic
adaptation occurs during prolonged Ab treatment that results
in lowering of the GSSG pool. Since the astrocytic GSH pool
also serves as an important cysteine reservoir for supporting
neuronal GSH synthesis via secretion and cleavage, the
smaller GSH pool size due to extended Ab exposure could
compromise this neuroprotective function of astrocytes.
CBS protein levels were diminished after repeated Ab but
not peroxide treatment (Fig. 3g). A similar trendwas observed
in cerebellar CBS levels and activity in AD versus control
samples, but did not reach statistical significance (Fig. 10).
This could have resulted from large inter-individual varia-
tions, the relatively small sample size as well as sample het-
erogeneity, that is, if decreased CBS were restricted to
astrocytes in AD, the difference would be underestimated in
tissue samples due to the presence of nonastrocytic cells. Since
CBS plays an important role both in GSH-linked redox ho-
meostasis (10, 35) and in H2S biogenesis (44), reduced ex-
pression of this protein inADbrain if seenmight be significant
in disease pathology. H2S, which modifies long-term poten-
tiation (1), is reported to be severely depressed in AD brain
(17). In addition, levels of S-adenosylmethionine, an allosteric
activator (18) and stabilizer (39) of CBS, are decreased in AD
brain, but not in idiopathic Parkinson’s disease patients,
suggesting that the change is not generally correlated with a
chronic neurodegenerative disease but may be AD specific
(34). Hence, upregulation of CBS expression or its activation
or stabilization might represent a specific therapeutic strategy
for alleviating redox perturbations associated with AD.
NAC treatment or catalase overexpression abrogated the
Ab-induced ROS generation (Fig. 2). Catalase or SOD over-
expression have been shown to decrease ROS levels and res-
cue neurons from the toxic action of the Ab peptide (16, 30),
consistent with overproduction of ROS contributing to neu-
rotoxicity. Our finding that catalase but not SOD1 levels were
diminished after repeated Ab treatment is consistent with the
earlier observation that brain catalase but not SOD activity is
decreased in patients with Alzheimer’s type dementia (23, 40).
Ferritin and catalase are potent suppressors of Ab toxicity
(41). For to be effective against Ab-induced ROS accumula-
tion, downstream antioxidant enzymes such as catalase and/
or GSH peroxidase, which remove H2O2, the product of SOD,
need to be also act in concert. A direct effect of Ab on catalase
has been shown, which resulted in deactivation of catalase
and increased cellular intracellular H2O2 (25). Although some
studies report decreased SOD activity (31, 48), others report
either no change (23, 40) or increased SOD activity in AD
patients compared with controls (28).
Clearly, the Ab effects on redox homeostasis are more
complex than simply being mediated via peroxide as pro-
posed (11). The aim of the present study was to determine
differences, if any in astrocytic responses to a specific (e.g., Ab)
versus a general (e.g., t-BuOOH) oxidant insult. In the present
study, we report for the first time, a detailed mechanistic
analysis of the redox changes in astrocytes in response to Ab
treatment. Although Ab treatment stimulates H2O2/ROS
production in astrocytes, the intra- and extra-cellular meta-
bolic responses are distinct from those of a nonspecific
oxidant, and await full mechanistic elucidation. In summary,
our study points to the importance of identifying AD-specific
redox markers that might be etiologically important and
could serve as potential therapeutic targets.
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GSSG¼ glutathione disulfide
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rpt¼ repeated
SAS¼ sulfasalazine
SOD¼ superoxide dismutase
t-BuOOH¼ tertiary-butylhydroperoxide
TUNEL¼ terminal deoxynucleotidyl transferase-
dUTP nick end labeling
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